Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Morgan

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Transplantation|December 25, 2010
T Lymphocyte responses to nonpolymorphic HLA-derived peptides are associated with chronic renal allograft dysfunctionHelen J Smith, Rajesh Hanvesakul, Andrew Bentall, et al.
American Journal of Nephrology|June 6, 2015
Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximabShivani Shah, Zdenka Hruskova, Marten Segelmark, et al.
Arthritis and Rheumatism|March 26, 2011
CD4+CD28- T cell expansion in granulomatosis with polyangiitis (Wegener's) is driven by latent cytomegalovirus infection and is associated with an increased risk of infection and mortalityMatthew D Morgan, Annette Pachnio, Jusnara Begum, et al.
Arthritis Research & Therapy|August 31, 2018
The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitisDimitrios Chanouzas, Michael Sagmeister, Lovesh Dyall, et al.
Kidney International|October 2, 2014
Successful outcome of pregnancy in patients with anti-neutrophil cytoplasm antibody-associated small vessel vasculitisAdam P Croft, Stuart W Smith, Sue Carr, et al.
Journal of Nephrology|May 20, 2015
Rituximab for treatment of severe renal disease in ANCA associated vasculitisDuvuru Geetha, Zdenka Hruskova, Marten Segelmark, et al.
Annals of the Rheumatic Diseases|March 6, 2015
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trialRachel B Jones, Shunsuke Furuta, Jan Willem Cohen Tervaert, et al.
The New England Journal of Medicine|July 22, 2010
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitisRachel B Jones, Jan Willem Cohen Tervaert, Thomas Hauser, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 2, 2010
Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort studyMartin J Landray, Jonathan R Emberson, Lisa Blackwell, et al.
Annals of the Rheumatic Diseases|December 1, 2011
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-upLorraine Harper, Matthew D Morgan, Michael Walsh, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Transplantation|December 25, 2010
T Lymphocyte responses to nonpolymorphic HLA-derived peptides are associated with chronic renal allograft dysfunctionHelen J Smith, Rajesh Hanvesakul, Andrew Bentall, et al.
American Journal of Nephrology|June 6, 2015
Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximabShivani Shah, Zdenka Hruskova, Marten Segelmark, et al.
Arthritis and Rheumatism|March 26, 2011
CD4+CD28- T cell expansion in granulomatosis with polyangiitis (Wegener's) is driven by latent cytomegalovirus infection and is associated with an increased risk of infection and mortalityMatthew D Morgan, Annette Pachnio, Jusnara Begum, et al.
Arthritis Research & Therapy|August 31, 2018
The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitisDimitrios Chanouzas, Michael Sagmeister, Lovesh Dyall, et al.
Kidney International|October 2, 2014
Successful outcome of pregnancy in patients with anti-neutrophil cytoplasm antibody-associated small vessel vasculitisAdam P Croft, Stuart W Smith, Sue Carr, et al.
Journal of Nephrology|May 20, 2015
Rituximab for treatment of severe renal disease in ANCA associated vasculitisDuvuru Geetha, Zdenka Hruskova, Marten Segelmark, et al.
Annals of the Rheumatic Diseases|March 6, 2015
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trialRachel B Jones, Shunsuke Furuta, Jan Willem Cohen Tervaert, et al.
The New England Journal of Medicine|July 22, 2010
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitisRachel B Jones, Jan Willem Cohen Tervaert, Thomas Hauser, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 2, 2010
Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort studyMartin J Landray, Jonathan R Emberson, Lisa Blackwell, et al.
Annals of the Rheumatic Diseases|December 1, 2011
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-upLorraine Harper, Matthew D Morgan, Michael Walsh, et al.
Pageof 3